Can you count on the new oral anticoagulants?

Presented by Peter Loewen at the 23rd Annual Drug Therapy Decision-Making Course, Vancouver, BC. April 20, 2012.

HANDOUT

REFERENCES from the talk

• ROCKET-AF
• RE-LY
• RE-LY Secondary Prevention
• RE-LY: Efficacy and safety of dabigatran compared with warfarin at different levels of INR control for stroke prevention in AF61194-4/abstract)
• AVERROES
• ARISTOTLE
• CCS Atrial Fib Guidelines Focused Update 201200046-3/abstract)
• CCS Atrial Fib Guidelines 2010
• ESC Task Force: New Oral Anticoagulants in Atrial Fibrillation and Acute Coronary Syndromes
• Dabigatran Association With Higher Risk of Acute Coronary Events
• Myocardial Ischemic Events in Patients With Atrial Fibrillation Treated With Dabigatran or Warfarin in the RE-LY Trial
• Emergency Hospitalizations for Adverse Drug Events in Older Americans
• • Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation-A Canadian payer perspective
• Cost-Effectiveness of Dabigatran for Stroke Prophylaxis in Atrial Fibrillation
• Cost-Effectiveness of Dabigatran Compared With Warfarin for Stroke Prevention in Patients With Atrial Fibrillation and Prior Stroke or TIA
• Cost-Effectiveness of Dabigatran Compared With Warfarin for Stroke Prevention in Atrial Fibrillation
• Dabigatran etexilate versus warfarin in management of non-valvular atrial fibrillation in UK context: quantitative benefit-harm and economic analyses
• • Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a ‘real world’ atrial fibrillation population

• RE-COVER: Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism

• EINSTEIN: Oral Rivaroxaban for Symptomatic Venous Thromboembolism
• EINSTEIN-PE: Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary Embolism